Elocalcitol

Modify Date: 2024-01-12 07:42:18

Elocalcitol structure	Common Name	Elocalcitol
	CAS Number	199798-84-0	Molecular Weight	442.65
	Density	N/A	Boiling Point	N/A
	Molecular Formula	C₂₉H₄₃FO₂	Melting Point	N/A
	MSDS	N/A	Flash Point	N/A

Use of Elocalcitol

Elocalcitol (BXL-628) is a selective, orally active vitamin D receptor (VDR) agonist. Elocalcitol shows anti-inflammatory activity. Elocalcitol inhibits growth of prostate cancer cells[1][2].

Name	(1R,3E,5S)-3-[(2E)-2-[(3aS,7aS)-1-[(E,2S)-6-ethyl-6-hydroxyoct-4-en-2-yl]-7a-methyl-3a,5,6,7-tetrahydro-3H-inden-4-ylidene]ethylidene]-5-fluoro-4-methylidenecyclohexan-1-ol
Synonym	More Synonyms

Description	Elocalcitol (BXL-628) is a selective, orally active vitamin D receptor (VDR) agonist. Elocalcitol shows anti-inflammatory activity. Elocalcitol inhibits growth of prostate cancer cells[1][2].
Related Catalog	Research Areas >> Cancer Signaling Pathways >> Vitamin D Related >> VD/VDR Research Areas >> Inflammation/Immunology
References	[1]. Mariani M, et al. The selective vitamin D receptor agonist, elocalcitol, reduces endometriosis development in a mouse model by inhibiting peritoneal inflammation. Hum Reprod. 2012 Jul;27(7):2010-9. [2]. Marchiani S, et al. The vitamin D analogue BXL-628 inhibits growth factor-stimulated proliferation and invasion of DU145 prostate cancer cells. J Cancer Res Clin Oncol. 2006 Jun;132(6):408-16.

Description

Elocalcitol (BXL-628) is a selective, orally active vitamin D receptor (VDR) agonist. Elocalcitol shows anti-inflammatory activity. Elocalcitol inhibits growth of prostate cancer cells[1][2].

Related Catalog

Research Areas >> Cancer

Signaling Pathways >> Vitamin D Related >> VD/VDR

Research Areas >> Inflammation/Immunology

References

[1]. Mariani M, et al. The selective vitamin D receptor agonist, elocalcitol, reduces endometriosis development in a mouse model by inhibiting peritoneal inflammation. Hum Reprod. 2012 Jul;27(7):2010-9.

[2]. Marchiani S, et al. The vitamin D analogue BXL-628 inhibits growth factor-stimulated proliferation and invasion of DU145 prostate cancer cells. J Cancer Res Clin Oncol. 2006 Jun;132(6):408-16.